Abstract: A secondary battery is provided. The secondary battery includes a cathode; an anode; and an electrolytic solution including a cyano compound.

Abstract: The present invention relates to a method of manufacturing a fluorocytosine-based compound of Formula I. The invention also relates to a compound obtained by such a method, a pharmaceutical drug substance and a method for its manufacture, a pharmaceutical composition, and also various uses in therapy of the compounds, pharmaceutical drug substances, and pharmaceutical compositions of the invention.

Abstract: A method for preparing a cyclic peptide, derivative or analogue thereof is described. The method comprises contacting a peptide, derivative or analogue thereof with a fluoro-heteroaromatic compound to cyclise the peptide, derivative or analogue thereof.

Abstract: The present invention relates to a method of manufacturing a fluorocytosine-based compound of Formula I. The invention also relates to a compound obtained by such a method, a pharmaceutical drug substance and a method for its manufacture, a pharmaceutical composition, and also various uses in therapy of the compounds, pharmaceutical drug substances, and pharmaceutical compositions of the invention.

Abstract: a secondary battery is provided. The secondary battery includes a cathode; an anode; and an electrolytic solution including a carbonyl compound.

Abstract: A method for chemically modifying a peptide, derivative or analogue thereof is described. The method comprises contacting a peptide, derivative or analogue thereof with a fluoro-heteroaromatic compound to activate the peptide, derivative or analogue thereof. The activated peptide, derivative or analogue thereof is then contacted with a nucleophile or base to create a chemically modified peptide, derivative or analogue thereof.

Abstract: The present invention relates to a method of manufacturing a fluorocytosine-based compound of Formula I. The invention also relates to a compound obtained by such a method, a pharmaceutical drug substance and a method for its manufacture, a pharmaceutical composition, and also various uses in therapy of the compounds, pharmaceutical drug substances, and pharmaceutical compositions of the invention.

Abstract: A method for preparing a cyclic peptide, derivative or analogue thereof is described. The method comprises contacting a peptide, derivative or analogue thereof with a fluoro-heteroaromatic compound to cyclise the peptide, derivative or analogue thereof.

Abstract: This invention relates to fluorinating agents and, more particularly, to chiral non-racemic fluorinating agents useful for enantioselective fluorination, as well as to their synthesis and use and other subject matter. The fluorinating agents are based on a substituted 1,4-diazabicyclo[2.2.2]octane (DABCO) skeleton and provide electrophillic fluorine enantioselectively.

Abstract: A method for chemically modifying a peptide, derivative or analogue thereof is described. The method comprises contacting a peptide, derivative or analogue thereof with a fluoro-heteroaromatic compound to activate the peptide, derivative or analogue thereof. The activated peptide, derivative or analogue thereof is then contacted with a nucleophile or base to create a chemically modified peptide, derivative or analogue thereof.

Abstract: This invention relates to fluorinating agents and, more particularly, to chiral non-racemic fluorinating agents useful for enantioselective fluorination, as well as to their synthesis and use and other subject matter. The fluorinating agents are based on a substituted 1,4-diazabicyclo[2.2.2]octane (DABCO) skeleton and provide electrophillic fluorine enantioselectively.

Abstract: The invention relates to a process for making HOF.RCN and using it to oxidise organic substrates in a quick and safe way. The process comprises passing diluted fluorine through a conduit and RCN in water through another conduit into a microreactor to form HOF.RCN and reacting this with an organic substrates.

Abstract: The present invention relates to a composition comprising at least one type of liquid crystal, to a liquid crystal cell and liquid crystal display device comprising such composition and to a method of preparing such a composition and/or such a liquid crystal cell.

Abstract: The invention relates to a process for making HOF.RCN and using it to oxidise organic substrates in a quick and safe way. The process comprises passing diluted fluorine through a conduit and RCN in water through another conduit into a microreactor to form HOF.RCN and reacting this with an organic substrates.

Abstract: The present invention relates to a composition comprising at least one type of liquid crystal, to a liquid crystal cell and liquid crystal display device comprising such composition and to a method of preparing such a composition and/or such a liquid crystal cell.

Abstract: A reactor for carrying out a reaction between at least two fluids comprises a reactor plate (20) with a plurality of grooves or through slots (22) in which the fluids mix and react and a separable overlying reservoir plate (2) for supplying the fluids to slots (22) from reservoirs (4, 6) via slots (10) a, (10) b, with a collecting conduit or reservoir (8) and slots (10) c for the product of the reaction. Reservoir plate (2) may lie between two reactor plates, or a single reactor plate (20) may lie between two reservoir plates. Third or further reservoirs may or may not be spaced from the second reservoir (6) depending on whether more than two fluids need to be present simultaneously, or whether a second reaction is required after the first two fluids have had time to react. Means may be provided for controlling the pressure in slots (22), the pressure differential (and flow rate) along slot (22), and/or the temperature in the reservoirs (4, 6) or slots (22).

Abstract: A reactor for carrying out a reaction between at least two fluids comprises a reactor plate (20) with a plurality of grooves or through slots (22) in which the fluids mix and react and a separable overlying reservoir plate (2) for supplying the fluids to slots (22) from reservoirs (4, 6) via slots (10) a, (10) b, with a collecting conduit or reservoir (8) and slots (10) c for the product of the reaction. Reservoir plate (2) may lie between two reactor plates, or a single reactor plate (20) may lie between two reservoir plates. Third or further reservoirs may or may not be spaced from the second reservoir (6) depending on whether more than two fluids need to be present simultaneously, or whether a second reaction is required after the first two fluids have had time to react. Means may be provided for controlling the pressure in slots (22), the pressure differential (and flow rate) along slot (22), and/or the temperature in the reservoirs (4, 6) or slots (22).

Abstract: There is provided a method of selectively replacing a carbon-hydrogen bond at an unactivated saturated sp3 hybridised carbon atom in an organic compound by a carbon-nitrogen bond, the method comprising reacting the compound with a fluorinating agent in a solvent reaction medium comprising a nitrile compound and providing a Lewis acid whereby the carbon-hydrogen bond is replaced by a carbon-nitrogen bond. Advantageously, the reaction may be performed in one stage and/or in one vessel. Advantageously, the method may be carried out at or just below ambient or room temperature.

Abstract: A method of fluorinating a heterocyclic organic compound comprises the step of reacting a heterocyclic compound with elemental fluorine in the presence of another halogen. The reaction may be conducted in the presence of a base.

Abstract: A process for the preparation of a selectively fluorinated organic compound, which process includes reaction of a precursor of said organic compound, the precursor containing at least one Group VI element selected from sulfur, selenium and tellurium, with a fluorinating agent and another halogenating agent and characterized in that the fluorinating agent is elemental fluorine.